Phase 1 study of combinatorial sorafenib, <scp>G‐CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3‐ITD</scp>‐mutated acute myelogenous leukemia patients

Gautam Borthakur, Michael Andreeff, Jörge E. Cortes et al.|American Journal of Hematology|2020

Cited by 38